| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Interest income | - | - | - | 15,445 |
| Revenues | - | 0 | - | - |
| Nonoperating income (expense) | - | - | - | 15,445 |
| Related party travel costs | - | 0 | - | - |
| General and administrative expenses | 386,951 | 5,027,071 | 1,850,786 | 5,378,744 |
| Research and development expenses | 759,525 | 42,839 | 336,996 | 627,434 |
| Total operating costs | 1,146,476 | 5,069,910 | 2,187,782 | 6,006,178 |
| Interest income | 44,182 | 1,362 | - | - |
| Interest income (expense), net | - | - | 7,954 | - |
| Interest expense | - | 1,342 | - | - |
| Net loss | -1,102,294 | -5,069,890 | -2,179,828 | -5,990,733 |
| Basic loss per share | -0.03 | 0.17 | -0.07 | -0.2 |
| Basic weighted average common stock shares outstanding | 32,398,906 | 30,010,165 | 29,762,671 | 29,609,814 |
| Diluted loss per share | -0.03 | 0.17 | -0.07 | -0.2 |
| Diluted weighted average common stock shares outstanding | 32,398,906 | 30,010,165 | 29,762,671 | 29,609,814 |
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)